ArticlemBio2019
Development of a Gold Nanoparticle Vaccine against Enterohemorrhagic Escherichia coli O157:H7.
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 54 citations in OpenAlex.
- Engineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease.Human vaccines & immunotherapeutics · 2026Review
- Nanoparticles as Delivery Vehicles for Vaccines: The Use of Gold Nanoparticles.Current pharmaceutical biotechnology · 2026Review
- Revolutionizing Nanovaccines: A New Era of Immunization.Vaccines · 2025Review
- Fecal microbiome alterations of mice following immunization with gold nanoparticle vaccines against enterohemorrhagic Escherichia coli.Gut pathogens · 2024Article
- Fecal Microbiome Alterations of Mice Following Immunization with Gold Nanoparticle Vaccines Against Enterohemorrhagic Escherichia coli.Research square · 2024Article
- Endogenous capsid-forming protein ARC for self-assembling nanoparticle vaccines.Journal of nanobiotechnology · 2024Article
- Further Evaluation of EnterohemorrhagicVaccines · 2024Article
- Efficacy of EHEC gold nanoparticle vaccines evaluated with the Shiga toxin-producingMicrobiology spectrum · 2024Article
- Nanotechnology Platform for Advancing Vaccine Development against the COVID-19 Virus.Diseases (Basel, Switzerland) · 2023Review
- Nanotherapeutics with immunoregulatory functions for the treatment of bacterial infection.Biomaterials research · 2023Review
- Bioengineered materials with selective antimicrobial toxicity in biomedicine.Military Medical Research · 2023Review
- Article
- A chimeric protein-based vaccine elicits a strong IgG antibody response and confers partial protection against Shiga toxin-producingFrontiers in immunology · 2023Article
- Diagnosis and Treatment for Shiga Toxin-ProducingToxins · 2022Review
- Genomics and pathotypes of the many faces of Escherichia coli.FEMS microbiology reviews · 2022Article
- Immunogenicity of inactivatedIranian journal of basic medical sciences · 2022Article
- Efficacy and Immune Response Elicited by Gold Nanoparticle- Based Nanovaccines against Infectious Diseases.Vaccines · 2022Review
- Optimization of Multivalent Gold Nanoparticle Vaccines Eliciting Humoral and Cellular Immunity in anmSphere · 2022Article
- Synthesis and immunogenicity assessment of a gold nanoparticle conjugate for the delivery of a peptide from SARS-CoV-2.Nanomedicine : nanotechnology, biology, and medicine · 2021Article
- Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines.Vaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here we exploit the natural properties of a synthetic nanoparticle (NP) scaffold as a subunit vaccine against enterohemorrhagic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.